title: Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).
abstract: With the objectives of clarifying the concepts related to "cardiometabolic risk," "metabolic syndrome" and "risk stratification" and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group presents an executive summary of a detailed analysis and position paper that offers a comprehensive and consolidated approach to the identification and management of cardiometabolic risk. The above concepts overlap and relate to the atherogenic process and development of type 2 diabetes. However, there is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. "Global cardiometabolic risk" is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider ethnicity-related risk factors in order to appropriately evaluate all individuals in their diverse patient populations.
authors: St. Michael's Hospital, Toronto, Ontario, Canada. LeiterL@smh.ca
authors: Lawrence A
authors: LA
authors: Leiter
authors: David H
authors: DH
authors: Fitchett
authors: Richard E
authors: RE
authors: Gilbert
authors: Milan
authors: M
authors: Gupta
authors: G B John
authors: GB
authors: Mancini
authors: Philip A
authors: PA
authors: McFarlane
authors: Robert
authors: R
authors: Ross
authors: Hwee
authors: H
authors: Teoh
authors: Subodh
authors: S
authors: Verma
authors: Sonia
authors: S
authors: Anand
authors: Kathryn
authors: K
authors: Camelon
authors: Chi-Ming
authors: CM
authors: Chow
authors: Jafna L
authors: JL
authors: Cox
authors: Jean-Pierre
authors: JP
authors: Després
authors: Jacques
authors: J
authors: Genest
authors: Stewart B
authors: SB
authors: Harris
authors: David C W
authors: DC
authors: Lau
authors: Richard
authors: R
authors: Lewanczuk
authors: Peter P
authors: PP
authors: Liu
authors: Eva M
authors: EM
authors: Lonn
authors: Ruth
authors: R
authors: McPherson
authors: Paul
authors: P
authors: Poirier
authors: Shafiq
authors: S
authors: Qaadri
authors: Rémi
authors: R
authors: Rabasa-Lhoret
authors: Simon W
authors: SW
authors: Rabkin
authors: Arya M
authors: AM
authors: Sharma
authors: Andrew W
authors: AW
authors: Steele
authors: James A
authors: JA
authors: Stone
authors: Jean-Claude
authors: JC
authors: Tardif
authors: Sheldon
authors: S
authors: Tobe
authors: Ehud
authors: E
authors: Ur
mesh_terms: D002170:Canada / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D015994:Incidence; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D009765:Obesity / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors